{"id":"W4307230056","doi":"10.1158/1078-0432.ccr-22-2235","title":"Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":227,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston; Novartis Pharmaceuticals UK Limited; University of Texas MD Anderson Cancer Center; F. Hoffmann-La Roche; Genentech; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Adverse effect; Sting; Internal medicine; Pharmacodynamics; Gastroenterology; Agonist; Refractory (planetary science); Pharmacokinetics; Pharmacology; Oncology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009206013,0.001073511,0.001435058,0.0003516118,0.0002374136,0.0006298312,0.0006440105,0.0006872343,0.00146767],"category_scores_gemma":[0.000380236,0.0003695336,0.0008909051,0.0003315987,0.0006120866,0.0005965104,0.0002422386,0.001729055,0.0004350844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005133073,"about_ca_system_score_gemma":0.0006971682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004971303,"about_ca_topic_score_gemma":0.0008484178,"domain_scores_codex":[0.9997382,0.0001090322,0.00001894821,0.00004837009,0.00003168801,0.00005383829],"domain_scores_gemma":[0.9997197,0.00003959044,0.00006058114,0.00003320139,0.00001751642,0.0001294841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4322464,0.1128112,0.01095792,0.001551231,0.002135699,0.0005576636,0.0005646301,0.005953738,0.2226284,0.0003603614,0.002923171,0.2073095],"study_design_scores_gemma":[0.2066933,0.7562623,0.01127554,0.0000403891,0.0006083167,0.0005367007,0.00007319159,0.002311892,0.01956545,0.0001281268,0.002475886,0.00002895616],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970422,0.00125185,0.0003839126,0.00009254451,0.00003534381,0.0004410031,0.0001862976,0.0000483553,0.00051863],"genre_scores_gemma":[0.996428,0.0009897079,0.0007297788,0.0001629066,0.00007363331,0.0004393855,0.0005277181,0.00001268133,0.0006363505],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00146767,"threshold_uncertainty_score":0.004909873,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2811211172679662,"score_gpt":0.5536109955576296,"score_spread":0.2724898782896634,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}